News

UK-listed AstraZeneca: ‘We are a very American company’

AstraZeneca’s chief executive has said the drugmaker is a “very American company” amid growing speculation it will shift its ...

AstraZeneca CEO doubles down on U.S. amid rumors of listing shift

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca share price forecast after earnings

AstraZeneca share price held steady this week after the company published strong financial results on Tuesday.

AstraZeneca Profit, Revenue Lifted by Cancer Drugs

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...
Fierce Biotech7h

AstraZeneca drops lead T-cell receptor therapy from $200M Neogene buy

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

AstraZeneca beats profit expectations on robust drug sales, US demand

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...
Explore more

Live: FTSE 100 Rises on Boost from Barclays, AstraZeneca

Jefferies analysts note that FX was a significant headwind and it wasn’t quite clear the extent to which that had been ...

AstraZeneca declares $1.03 dividend

AstraZeneca (NASDAQ:AZN) has announced an interim dividend of $1.03/share. The record date for the first interim dividend for 2025, payable on September 8, 2024, will be August ...